Media System Lab’s Post

We are thrilled to announce that our paper exploring the role of Smpd3 in EV biogenesis is now published in International Society for Extracellular Vesicles (JExBio)! We took a novel approach beyond common pharmacological inhibitors by creating both full-body and conditional Smpd3 knockout (KO) mice. Surprisingly, we observed no effect on EV release upon absence of Smpd3. 🔬 Here's a summary: Neutral sphingomyelinases (nSMases), particularly nSMase 2 encoded by the Smpd3 gene, are conventionally believed to play crucial roles in EV biogenesis. Studies often suggest that their inhibition, using drugs like GW4869, reduces EV production. However, these inhibitors can have limitations such as off-target effects and lack of specificity. To better understand Smpd3's role, we employed CRISPR/Cas9 technology to develop heterozygous full-body and conditional Smpd3 KO mouse lines. Contrary to expectations, Smpd3 deficiency did not affect EV release, both in vivo and in specific cells such as mixed cortical cultures and bone marrow derived macrophages. Our findings suggest that Smpd3's role in EV biogenesis might vary depending on cell type or species, indicating its effects are not universally consistent across different cellular contexts. https://lnkd.in/eJTFP2JG

Our second paper on PVL is now in print! This study represents the first Whole Exome Sequencing genome wide characterization of the mutational landscape of PVL and provides insight into carcinogenic mechanisms in this difficult-to-diagnose and treat condition. Our findings identify both known and novel oncogenic mechanisms in PVL. Another step forward in our understanding of the molecular landscape and potential therapies for oral premalignant conditions. Genome-wide characterization of the mutational landscape of proliferative verrucous leukoplakia. Farah CS, Shearston K, Melton PE, Fox SA. Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Jul;138(1):99-111. doi: 10.1016/j.oooo.2024.04.005. Epub 2024 Apr 14. PMID: 38760284 https://lnkd.in/gAAJaJyq

The American Heart Association has issued an important scientific statement recommending the use of CYP2C19 genetic testing before prescribing Clopidogrel. Clopidogrel, a prodrug, is the most used oral P2Y12 inhibitor (antiplatelet agent) and is activated primarily after being metabolized by a highly polymorphic hepatic cytochrome CYP2C219 enzyme. Loss-of-function genetic variants in CYP2C219 are common, can result in decreased active metabolite levels and increased on-treatment platelet aggregation, and are associated with increased ischemic events on clopidogrel therapy. Such patients can be identified by CYP2C19 genetic testing and can be treated with alternative therapy. This step aims to reduce the risk of secondary heart attacks and strokes after PCI interventions. Pharmacogenomics is key to improving patient outcomes and safety. #AmericanHeartAssociation #Cardiology #Clopidogrel #GeneticTesting #CYP2C19 #PatientSafety #PersonalizedMedicine #Pharmacogenomics Citation: CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.

This retrospective cohort study leveraged a novel national linkage of genomic data from the Decipher Genomic Classifier (GC) and real-world data to evaluate Decipher GC prognostic performance. The study, consisting of 58,935 patients tested and treated following prostate biopsy or radical prostatectomy in the real-world setting, assessed whether Decipher GC results associated with key outcomes, biochemical recurrence and metastasis. The findings align with those derived from controlled settings, and support the external prognostic validity of the Decipher GC in the real-world practice across patient populations and treatment settings. Click the link to learn more: https://lnkd.in/g2Jq_Xa6

🔬 New Research Alert! published in #DrugDevIndPharm 🌟 Liposomal delivery of Annona muricata leaves extract for the treatment of hepatocellular carcinoma 🌟 This study explores the potential of liposomal delivery of Annona muricata leaves extract for treating hepatocellular carcinoma (HCC). Researchers developed and characterized liposomes loaded with methanolic extract from A. muricata leaves, which showed promising results in both in-vitro and in-vivo experiments. The extract demonstrated significant anticancer activity against human hepatoma cells (HEPG2) with an IC50 of 17 ± 1.8 μg/mL. The optimized liposomal formulation exhibited favorable characteristics, including a particle size of 107.2 ± 1.7 nm, zeta potential of -30.6 mV, and entrapment efficiency of 62.15%. In-vivo studies on Swiss albino mice revealed the formulation's potential efficacy in treating HCC, supported by histopathological evidence. This research highlights the promising role of A. muricata extract-loaded liposomes as a novel approach for HCC treatment. 📖 Read the full article here: https://lnkd.in/g9P_p3s2 #CancerResearch #Liposomes #NaturalMedicine #HepatocellularCarcinoma #DrugDelivery #PharmaceuticalInnovation #Phytotherapy

📢 Exciting News in Skin Cell Research! 🧬 We're thrilled to share that our AssayGenie product played a crucial role in a recent breakthrough study published in Scientific Reports! The research delved into the effects of salicylate on epithelial actin reorganization, AMPK activation, and its implications for wound healing and contraction in mice. 🔬 Key Highlights: Our C/EBP-beta (Phospho-Thr235/188) Colorimetric Cell-Based ELISA Kit was instrumental in evaluating the activity of CEBPB and P300/CBP, showing that these molecules were not significantly altered by salicylate. Check our product by following the link here ➡ https://lnkd.in/etgBySSr 📈 The study's findings highlight the potential of salicylate in promoting wound healing, with our assays providing essential insights into the molecular mechanisms involved. 🛠️ At AssayGenie, we're committed to empowering researchers with the tools they need to push the boundaries of science. We're proud to have contributed to this significant advancement in understanding skin cell dynamics and wound healing. Check out the full study for more details: https://lnkd.in/eKwc3HYW #Research #Biotechnology #WoundHealing #SkinCellResearch #AssayGenie #ScientificReports #AMPK #Salicylate #CEBPB #P300CBP #ELISA #CellBiology #BiomedicalResearch

Celentyx is a CRO with a deep understanding of the impact of investigational drugs on human #microglia. Despite their importance in #neuroinflammation and #neurodegenerative diseases, working with human microglia is challenging. One of the solutions the Celentyx team have developed differentiates human peripheral blood monocytes into microglia (based upon their expression phenotype and function). These induced microglia are used a wide range of robust assays to study drug impact on microglial function including cytokine release (#NLRP3-dependent and independent), changes in expression of activation markers, #NFkB translocation and monitoring of #phagocytosis in real-time with pathology-relevant cargos. These assays have enabled the identification and development of modulators of #neuroinflammation. Join Professor Nicholas Barnes PhD, FBPhS PhD, FBPhS (Celentyx’s CEO) at our poster session sharing exciting data showcasing the phenotype, function and pharmacological impact of purinergic modulators using our human microglia platform. To discuss how this service can support your project stop by the poster or send us a message to set up a meeting. https://lnkd.in/d9BQg2Bk #elrig #drugdiscovery #elrigdd24

In this video, we feature the MIMETAS OrganoReady® Colon Organoid! This 3D Human Colon Organoid tubule, stained for tight junction (Occludin, green) and cell nuclei (blue), is the first ready-to-use adult stem cell-derived solution offered license-free for commercial use. We offer a fully characterized gastrointestinal model delivered straight to your lab, ensuring that it captures human intestinal processes and enables more accurate predictions of drug responses. Through our fee-for-services, we also build on top of this model in house, with the incorporation of other key cellular players and disease phenotypes at scale. In this upcoming webinar, learn how we capture the complexity of inflammatory bowel disease from multiple angles, enabling more accurate predictions of drug responses. Register for our live webinar: https://lnkd.in/edQbawru Learn more about the model: https://lnkd.in/egjYn_D6

#Omics studies in #precisionmedicine enable comprehensive analysis of genome, transcriptome, proteome, metabolome, and microbiome, aiding in novel discoveries and potential therapeutic targets, as highlighted in the paper. #healthcare #medicine #personalizedmedicine #precisionhealth #translationalmedicine #translationalprecisionmedicine #translationalresearch

Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases. 👉 Read More: dmdwarrior.com #dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #dyne #dyne251 #dyne101